Stocks
ALX Oncology Holdings (ALXO) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 4 619% | 93 423% | 1 222% | 6 896% | 11 130% | 4 456% | |||
| Changes by years, y/y, % | +2 893pp | +88 803pp | -92 200pp | +5 673pp | +4 234pp | +45.2% | |||
ALX Oncology Holdings. R&D/CAPEX, %
ALX Oncology Holdings. R&D/CAPEX, changes, pp
ALX Oncology Holdings (ALXO) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| R&D/CAPEX, % | 3 589% | 1 695% | 3 512% | 28 232% | 21 430% | 4 456% | ||
| Changes by years, y/y, % | +690pp | -8 712pp | -11 791pp | +21 755pp | +17 842pp | |||
| Changes by quarters, q/q, % | -2 889pp | -1 893pp | +1 817pp | +24 720pp | -6 802pp | |||
